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the study. Propensity scores, which predicted exposure to antidepressant agents,
were used to create propensity score-matched, propensity score-stratified, and
propensity score-adjusted logistic regression models. RESULTS: A total of 44,715
patients formed the study sample. The risk estimates varied across different ana-
lyticmethods. The propensity score-matched logistic regressionmodel yielded the
highest risk estimate (Relative Risk [RR]  1.452; 95% Confidence Interval [CI]: 1.276 –
1.651), followed by themultivariable-adjusted logistic regressionmodel (RR1.319;
95% CI: 1.067 – 1.630) and the propensity score-stratified logistic regression model
(RR1.153; 95% CI: 1.033 – 1.287). The propensity score-adjusted regression model
yielded the smallest risk estimate (RR1.080; 95% CI: 0.968 – 1.205). CONCLUSIONS:
Propensity score techniques using pharmacy claims data with a limited number of
covariates yielded varying estimates of the treatment effect. The choice of the
propensity score technique may influence the magnitude of the treatment effect
estimate.
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OBJECTIVES: To determine whether current use of antidepressants is associated
with increased risk of type 2 diabetesmellitus compared to former use.METHODS:
A nested case-control study was conducted within a cohort of 35,552 patients with
new antidepressant prescriptions from January 1, 2002 to December 31, 2009 using
Texas Medicaid. Patients aged 18-64 years and without diabetes at cohort entry
were included in the study. Antidepressant exposure was classified as current use
(within 6 month of diabetes diagnosis) and former use (6 months before diabetes
diagnosis). Conditional logistic regression was used to address the study objective.
RESULTS: A total 2,507 cases of incident diabetes and 10,028 matched control pa-
tients were identified. The average age was 44.9 (SD13.0) and themajority (75.6%)
were female. Compared to former use, current use of antidepressants was associ-
ated with a 2.1-fold increase in the risk of diabetes (Odds Ratio [OR]  2.108; 95%
Confidence Interval [CI]: 1.520 – 2.923). Compared to former use, current use of
tricyclic antidepressants (TCAs; OR2.279; 95% CI: 1.344 – 3.865), selective sero-
tonin reuptake inhibitors (SSRIs; OR2.241; 95% CI: 1.539 – 3.263), serotonin-nor-
epinephrine reuptake inhibitors (SNRIs; OR1.938; 95% CI: 1.135 – 3.310), and Other
(OR1.769; 95%CI: 1.090 – 2.872) were associatedwith an increased risk of diabetes.
Among current antidepressant users, there were no significant differences in the
risk of diabetes for SSRIs (OR0.833; 95% CI: 0.564 – 1.232), SNRIs (OR0.787; 95% CI:
0.480 – 1.280), and Other (OR0.673; 95% CI: 0.428 – 1.057), compared to TCAs.
CONCLUSIONS: Compared to former use, current use of antidepressants was as-
sociated with a two-fold increase in the risk of diabetes mellitus. This association
was also observedwhen current users of TCAs, SSRIs, SNRIs, andOther antidepres-
sants were compared with former users.
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OBJECTIVES: To determine whether: 1) use of antidepressants, compared to ben-
zodiazepines, increases the risk of type 2 diabetes mellitus; 2) individual antide-
pressant classes, compared to benzodiazepines, increases the risk of type 2 diabe-
tes; and 3) there are differences in the risk of type 2 diabetes among antidepressant
classes. METHODS: A retrospective cohort study using the Texas Medicaid pre-
scription claims database was conducted from January 1, 2002 to December 31,
2009. Patients aged 18-64 years with new prescriptions for antidepressant agents
(exposed) and benzodiazepines (unexposed) and without diabetes at cohort entry
constituted the base study population. Logistic regression analyses were used to
address the study objectives. RESULTS: A total of 44,715 patients formed the study
sample. Of these, 35,552 were exposed and 9,163 were unexposed. The average age
was 38.6 (SD14.2) and the majority (69.3%) were female. Use of antidepressants
was associated with an increased risk of diabetes (Relative Risk [RR]  1.396; 95%
Confidence Interval [CI]: 1.126 – 1.729) compared to benzodiazepine use, after con-
trolling for age, gender, medication adherence, persistence, number of diabeto-
genic medications, Chronic Disease Score, treatment duration, and year of cohort
entry. Compared to benzodiazepines, tricyclic antidepressants (TCAs; RR1.445;
95% CI: 1.057 – 1.977), serotonin-norepinephrine reuptake inhibitors (SNRIs;
RR1.593; 95% CI: 1.160 – 2.186), and selective serotonin reuptake inhibitors (SSRIs;
RR1.317; 95% CI: 1.037 – 1.673), were associated with an increased risk for diabe-
tes. Compared to TCAs, there were no significant differences in the risk of diabetes
for SSRIs (RR0.876; 95% CI: 0.678 – 1.132), SNRIs (RR1.003; 95% CI: 0.734 – 1.371)
and Other antidepressants (RR0.785; 95% CI: 0.582 – 1.058). CONCLUSIONS: Over-
all, use of antidepressants was associated with an increased risk of diabetes mel-
litus compared to benzodiazepine use. This association was also observed when
tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin-
norepinephrine reuptake inhibitors were compared to benzodiazepines.
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OBJECTIVES: Understanding the benefit-risk profiles of medications for type 2 di-
abetes (T2D) is of high public health interest. We assessed the potential compara-
tive health benefits and risks of exenatide onceweekly (ExQW) compared to insulin
glargine (IG) under various assumptions about hypothetical risks from pancreatic
and thyroid cancer associated with either treatment. METHODS: Safety and effi-
cacy data from the randomized controlled DURATION-3 trial were incorporated
into the CORE Diabetes Model to predict long-term health outcomes; pancreatic
and thyroid cancer risks from SEER (general population); i3/MarketScan claims
databases (T2D and/or therapy) were incorporated into derived Markov model.
Incremental net health benefit (INHB) was estimated in life years (LYs) and quality-
adjusted life years (QALYs) (both discounted at 3%) for different timehorizons (base
case30 years) and different assumptions about cancer risks. The incidence rate of
pancreatic cancer was 1.17/10,000 population/year. In the base-case scenario no
increased pancreatic cancer risk from ExQWand relative risk (RR) of 1.25 for IGwas
assumed. The risk for thyroid cancer was assumed same as in general population
and equal for ExQW and IG. In two alternative scenarios for pancreatic cancer risk:
a) assuming IG RR1.33 and ExQW having no increased risk, and b) assuming
ExQW RR1.07 and IG RR1.25. RESULTS: The INHB for ExQW versus IG was 0.118
Lys and 0.239 QALYs in basecase; 0.119 LYs and 0.239 QALYs in scenario a); and
0.118 LYs and 0.238 QALYs in scenario b). Neither scenario a) or b) changed INHB by
more than1%. The INHB for ExQW remained positive under different assumptions
about time horizon and risk levels. CONCLUSIONS: In all scenarios modeled, the
INHB for ExQWwas positive compared to IG. This study suggests that the potential
benefits from ExQW in reducing established T2D complications are expected to
outweigh hypothetical risks from pancreatic and thyroid cancer.
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OBJECTIVES: The objective of the current study is to assess the short-term associ-
ation between antidepressant drug use and the risk of new-onset diabetes using
two years of observation. METHODS: This study used the longitudinal data on
26,990 adults over age 21 from the Medical Expenditure Panel Survey (MEPS), a
large-survey of families and individuals to produce national estimates of health-
care use and expenditures. We pooled longitudinal data for years 2004-2007. De-
pression and diabetes status were identified from the MEPS household files and
medical condition files. Antidepressant use was derived from prescription drug
reports. Chi-square tests and logistic regressions were used to examine the link
between antidepressant use interacted with depression, and new-onset diabetes,
after controlling for demographic, socio-economic, healthcare access, health sta-
tus, and life-style risk factors (obesity, smoking, and physical activity). The inde-
pendent variables were entered in blocks. RESULTS: Antidepressants use was re-
ported in 11% of individuals. In unadjusted models, the risk of new-onset diabetes
was significantly increased for persons using antidepressants with depression
((AOR2.12) compared with those who did not have either. When lifestyle risk
factors were entered in the model, statistical significance disappeared. Indepen-
dently, lifestyle risk factors significantly increased the risk of new-onset diabetes:
hypertension, lipid disorders, obesity, and no physical exercise. CONCLUSIONS:
We found no association between new onset diabetes and antidepressant use and
confirmed the association between life-style risk factors and new-onset diabetes.
Future studies on the risk of new-onset diabetes by duration and intensity of anti-
depressant use and depressive symptoms are needed.
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OBJECTIVES: Diabetes represents a burden to the health care system due to its
increasing rates of incidence, morbidity andmortality. Epidemiological data is cru-
cial for policy and decision making to clarify gaps in the current health program
and to develop new ones. We decided to review the status of the population regis-
tered at Hiperdia program in order to better understand the real situation of these
diseases.METHODS: HIPERDIA is a program for monitoring hypertensive/ diabetic
outpatients under the public healthcare system care. Based on that database, we
searched the general profile of this population from 2002 until 2010 focusing on
type 2 diabetes (T2DM) and T2DM plus hypertension, and also geographical distri-
bution, gender, age and overweight/ obesity prevalence were raised. RESULTS:
From 2002 to 2010, a total of 2,199,972 people with T2DM and T2DM plus Hyperten-
sion were registered in the database, with 12.5 % presenting T2DM only and 87.5 %
with both conditions, which represents about 1.5% of the total population under
the public healthcare system. For patients with T2DM only we found 114,836 men
and 159,581 women (41.8% and 58.2%) and for patients with both conditions we
found 619,005 men and 1,306,550 women (32.1% and 67.9%). Regarding age, the
majority of the patients are in between 50 - 70 years-old. Almost 50% of the patients
are distributed within 5 states SP, MG, BA, PR and RJ. Overweight or obesity was
present in 48% of this population. CONCLUSIONS: In accordance with epidemio-
logical data, most of the diabetic patients in this database are middle-age, women
and almost half of them are obese or overweight. Added to that, our estimates
about diabetes prevalence were different from the number reported by the Brazil-
ian MoH at 2008 (9.7%).
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